Vertex Pharmaceuticals Incorporated (VRTX) Is Attracting Investor Attention: Here Is What You Should Know
Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?
Vertex Pharmaceutical Inc. (VRTX): Jim Cramer's Go-To Stock For Success
Vertex Pharmaceuticals Hits 4-week High
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $515
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Vertex to Participate in Upcoming September Investor Conferences
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today
The AI Trade Is Over, BofA Says. What to Buy Instead.
Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Vertex Pharmaceuticals: A Cautious Hold Amidst Mixed Financial Signals and Pipeline Uncertainty
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
The RMR Group Announces Vertex Pharmaceuticals' 15-Year Lease Renewal for 1.1 Million Square Feet in Boston's Seaport District
10 Health Care Stocks With Whale Alerts In Today's Session
Vertex Pharmaceuticals Insider Sold Shares Worth $602,447, According to a Recent SEC Filing